Showing results (2281-2290 of 3,086) with videos related to

Sort By:
Pageof 309
Drug Safety|November 21, 2023
Comparative Analysis of Information Provided in German Adverse Drug Reaction Reports Sent by Physicians, Pharmacists and ConsumersPatrick Christ, Diana Dubrall, Matthias Schmid, et al.
Drug Safety|November 16, 2023
Cognitive Safety is Largely Ignored in Clinical Drug Trials: A Study of Registered Study ProtocolsArne Reimers, Hanna Ljung
Drug Safety|October 30, 2023
Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar LaunchSreedhar Sagi, Pradeep Anjaneya, Sameer Kalsekar, et al.
Drug Safety|November 5, 2023
Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in FranceSibylle de Germay, Allison Singier, Francesco Salvo, et al.
Drug Safety|November 1, 2023
Drug Utilisation Patterns of Alternatives to Ranitidine-Containing Medicines in Patients Treated with Ranitidine: A Network Analysis of Data from Six European National DatabasesJohnmary T Arinze, Maria A J de Ridder, Dina Vojinovic, et al.
Drug Safety|October 7, 2023
Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network StudyOskar Gauffin, Judith S Brand, Sara Hedfors Vidlin, et al.
Drug Safety|July 25, 2023
Managing Cardiovascular and Cancer Risk Associated with JAK InhibitorsVictor Yang, Tue W Kragstrup, Christopher McMaster, et al.
Drug Safety|July 7, 2023
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance AssessmentYamin Shu, Lei Wang, Yiling Ding, et al.
Drug Safety|August 2, 2023
Use of Bisphosphonates and the Risk of Skin Ulcer: A National Cohort Study Using Data from the French Health Care Claims DatabaseClément Jambon-Barbara, Claire Bernardeau, Julien Bezin, et al.
Drug Safety|August 9, 2023
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New ZealandMuireann Walton, Vadim Pletzer, Thomas Teunissen, et al.
Pageof 309